Get the Stockscreener App
2.51
0.79%
-0.02
After Hours:
2.55
0.04
+1.59%
Grace Therapeutics Inc stock is traded at $2.51, with a volume of 165.20K.
It is down -0.79% in the last 24 hours and up +9.13% over the past month.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
See More
Previous Close:
$2.53
Open:
$2.54
24h Volume:
165.20K
Relative Volume:
0.24
Market Cap:
$40.85M
Revenue:
-
Net Income/Loss:
$-5.98M
P/E Ratio:
-6.9664
EPS:
-0.3603
Net Cash Flow:
$-9.83M
1W Performance:
+10.57%
1M Performance:
+9.13%
6M Performance:
-32.71%
1Y Performance:
-16.33%
1-Day Range:
$2.42
$2.58
1-Week Range:
$2.22
$2.58
52-Week Range:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.51 | 41.17M | 0 | -5.98M | -9.83M | -0.3603 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Grace Therapeutics (GRCE) price target decreased by 47.83% to 6.12 - MSN
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Drives EPS Beat, but Stock DeclinesPeak Earnings Alert - dars.gov.et
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics, Inc.(NasdaqCM:GRCE) added to Russell Microcap Value Benchmark Index - marketscreener.com
Grace Therapeutics, Inc.(NasdaqCM: GRCE) added to Russell 3000E Index - marketscreener.com
Grace Therapeutics, Inc.(NasdaqCM: GRCE) added to Russell Microcap Index - marketscreener.com
Grace Therapeutics, Inc.(NasdaqCM: GRCE) added to Russell 3000E Value Benchmark - marketscreener.com
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Should I Buy - Intellectia AI
Grace Therapeutics, Inc. Actuals & Estimates (NASDAQ:GRCE) - TradingView
GRCE Forecast — Price Target — Prediction for 2027 - TradingView
Quarterly GDP Featured in U.S. Next Week - Baystreet.ca
Quarterly GDP Featured In U.S. Next Week - Menafn
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Grace Therapeutics (NASDAQ: GRCE) Reports FDA CRL, Schedules Meeting - Value The Markets
Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104 - GuruFocus
Grace Therapeutics narrows FY26 net loss to $7.8 million - scanx.trade
Grace Therapeutics, Inc (GRCE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Grace Therapeutics, Inc (GRCE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Grace Therapeutics, Inc (GRCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Grace Therapeutics Reports 2026 Financial Results, Advances GTx-104 NDA Resubmission for aSAH Treatment After FDA CRL – STRIVE-ON Phase 3 Data Highlights and IP Expansion – Minichart - Minichart
Grace Therapeutics Updates GTx-104 Regulatory and Trial Progress - TipRanks
Grace Therapeutics (NASDAQ: GRCE) updates GTx-104 data, FDA CRL response and cash - Stock Titan
Grace Therapeut reports $7.8M net loss, $17.0M cash at FY2026 year-end - TradingView
GRCE: Net loss narrowed as GTx-104 advanced toward FDA resubmission, with strong trial results and IP gains - TradingView
Grace Therapeutics (NASDAQ: GRCE) narrows 2026 loss and details FDA path for GTx-104 - Stock Titan
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update - Moomoo
Grace: Fiscal Q4 Earnings Snapshot - marketscreener.com
Grace Therapeutics FY 2026: Net loss $(7.8)M, EPS $(0.47) — 10-K Summary - TradingView
GRCE: Net loss improved to $7.8M as R&D spending fell, but FDA CRL delays GTx-104 approval - TradingView
Grace Therapeutics (Nasdaq: GRCE) faces GTx-104 FDA CRL and writes down two pipeline drugs - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 - marketscreener.com
Grace Therapeutics, Inc (GRCE) Institutional Confidence - TradingKey
Grace Therapeutics reports 2026 fiscal results - grafa.com
Grace Therapeutics, Inc (GRCE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Grace Therapeutics, Inc (GRCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Grace Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - Stocktwits
GRCE Q4'25 Earnings: revenue estimate is 0 USD - TradingView
GRCE Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor ConfidenceReturn On Capital - newsline.com
GRCE Q1 2026 Earnings: EPS Beats Estimates by Wide Margin Amid No Reported RevenueEarnings Yield Spread - newsline.com
GRACE THERAPEUTICS INC (GRCE) Stock Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Connect - ACCESS Newswire
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Grace Therapeutics, Inc. (GRCE) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Grace Therapeutics, Inc. (GRCE) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz - The National Law Review
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-06-07 | Grace Therapeutics, Inc. (GRCE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:GRCE | Press Release - Stockhouse
We're Keeping An Eye On Grace Therapeutics' (NASDAQ:GRCE) Cash Burn Rate - Sahm
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):